| Name | Erucin |
| Description | Erucin （1-isothiocyanato-4-methylsulfanylbutane） is a dietary isothiocyanate produced by enzymatic hydrolysis of glucoErucin with potential cancer preventive effects, involved in apoptosis and cell cycle blockade through PARP-1 cleavage, p53 and p21，Cyp450, quinone reductase (QR), glutatione transferase (GST) and other pathways. |
| In vitro | In LPS-stimulated RAW 264.7 macrophages, Erucin (2.5 and 5 μmol/L) inhibited NO and PGE₂ production, suppressed NF-κB activity, and reduced expression of TNF-α, IL-6, IL-1β, iNOS, and COX-2[1]. In SH-SY5Y neuroblastoma cells, Erucin (5 μM) activated the Nrf2 pathway, increased intracellular GSH levels, and protected against 6-OHDA-induced oxidative stress[2]. Erucin (30–100 μM) inhibits proliferation and migration, induces apoptosis, releases H₂S, and reduces ERK1/2 phosphorylation in AsPC-1 pancreatic cancer cells[3]. |
| In vivo | In a TPA-induced mouse ear edema model, Erucin (100 and 300 nmol) significantly reduced swelling and decreased iNOS and COX-2 expression[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (496 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (20.46 mM), Sonication is recommended.
|
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Naringin | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Lung Cancer Compound Library | Ferroptosis Compound Library | Food Sourced Compound Library | Bioactive Compound Library | Selected Plant-Sourced Compound Library | Multi-Target Compound Library | Natural Product Library | Natural Product Library for HTS | Bioactive Compounds Library Max | Human Metabolite Library | Transcription Factor-Targeted Compound Library |
United States
